Ischemia‐modified albumin and advanced oxidation protein products as potential biomarkers of protein oxidation in A lzheimer's disease

Background The aim of the present study was to determine the systemic levels of oxidative stress markers, such as ischemia‐modified albumin ( IMA ), advanced oxidation protein products ( AOPP ), ferric reducing antioxidant power ( FRAP ) and the prooxidant–antioxidant balance ( PAB ), to clarify protein redox homeostasis in patients with A lzheimer's disease, and to compare them with mentally healthy persons of the same age. Methods A total of 38 patients with A lzheimer's disease ( AD ) and 34 sex‐ and age‐matched mentally healthy control subjects were included in this study. Results The patients had significantly higher AOPP , IMA and PAB in the patient group than in the control group ( P  = 0.004, P  = 0.001, P  = 0.007, respectively). The FRAP was significantly lower in the patients with AD than in the control subjects ( P  = 0.002), and according to the receiver operating characteristic curves, the IMA and AOPP areas are below the 0.700 receiver operating characteristic curve line (area under the curve 0.817 and 0.730, respectively; 95% CI 0.709–0.898 and 0.612–0.828, respectively). Conclusions Increased IMA , AOPP and PAB, and decreased FRAP are likely to be results of oxidative stress, a condition in which an imbalance occurs between the production and inactivation of reactive oxygen species in AD . The IMA could be used for the better evaluation of clinical status, as well as the independent characteristic symptoms of AD , for the purposes of routine clinical laboratory analysis. Geriatr Gerontol Int 2015; 15: 872–880.